[go: up one dir, main page]

WO2008046964A3 - Nouveaux inhibiteurs utiles - Google Patents

Nouveaux inhibiteurs utiles Download PDF

Info

Publication number
WO2008046964A3
WO2008046964A3 PCT/FI2007/050557 FI2007050557W WO2008046964A3 WO 2008046964 A3 WO2008046964 A3 WO 2008046964A3 FI 2007050557 W FI2007050557 W FI 2007050557W WO 2008046964 A3 WO2008046964 A3 WO 2008046964A3
Authority
WO
WIPO (PCT)
Prior art keywords
useful inhibitors
novel useful
relates
novel
hypoxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FI2007/050557
Other languages
English (en)
Other versions
WO2008046964A2 (fr
WO2008046964A8 (fr
Inventor
Panu Jaakkola
Pekka Heikkinen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20065656A external-priority patent/FI20065656A0/fi
Application filed by Individual filed Critical Individual
Publication of WO2008046964A2 publication Critical patent/WO2008046964A2/fr
Publication of WO2008046964A3 publication Critical patent/WO2008046964A3/fr
Anticipated expiration legal-status Critical
Publication of WO2008046964A8 publication Critical patent/WO2008046964A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé et un essai permettant d'identifier des têtes de série thérapeutiques utiles pour traiter, prévenir et/ou soulager des troubles associés à une hypoxie et/ou un signal TGF-β. L'invention concerne en outre des compositions pharmaceutiques et des procédés permettant de détecter des modifications malignes.
PCT/FI2007/050557 2006-10-16 2007-10-16 Nouveaux inhibiteurs utiles Ceased WO2008046964A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85174206P 2006-10-16 2006-10-16
US60/851,742 2006-10-16
FI20065656 2006-10-16
FI20065656A FI20065656A0 (fi) 2006-10-16 2006-10-16 Uusia käyttökelpoisia inhibiittoreita

Publications (3)

Publication Number Publication Date
WO2008046964A2 WO2008046964A2 (fr) 2008-04-24
WO2008046964A3 true WO2008046964A3 (fr) 2008-07-10
WO2008046964A8 WO2008046964A8 (fr) 2009-07-30

Family

ID=39314394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2007/050557 Ceased WO2008046964A2 (fr) 2006-10-16 2007-10-16 Nouveaux inhibiteurs utiles

Country Status (1)

Country Link
WO (1) WO2008046964A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
WO2009047532A2 (fr) * 2007-10-12 2009-04-16 Cancer Research Technology Limited Loci de sensibilité au cancer
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064770A2 (fr) * 2003-01-17 2004-08-05 Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services Utilisation d'un inhibiteur de smad3 dans le traitement d'une fibrose dependant de la transition epithelium-mesenchyme comme dans l'oeil et le rein
US20050164295A1 (en) * 2001-06-11 2005-07-28 Hoffmann F. M. Screen for selective inhibitors or activators of smad protein function

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164295A1 (en) * 2001-06-11 2005-07-28 Hoffmann F. M. Screen for selective inhibitors or activators of smad protein function
WO2004064770A2 (fr) * 2003-01-17 2004-08-05 Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services Utilisation d'un inhibiteur de smad3 dans le traitement d'une fibrose dependant de la transition epithelium-mesenchyme comme dans l'oeil et le rein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIN X. ET AL.: "PPM1A functions as a SMAD phosphatase to terminate TGFbeta signaling", CELL, vol. 125, no. 5, June 2006 (2006-06-01), pages 915 - 928 *
NAKAGAWA T. ET AL.: "Differential regulation of VEGF by TGF-beta and hypoxia in rat proximal tubular cells", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 287, no. 4, October 2004 (2004-10-01), pages F658 - F664 *
NAKAO A. ET AL.: "Identification of Smad7, a TGF-beta-inducible antagonist of TGF-beta signalling", NATURE, vol. 389, no. 9, October 1997 (1997-10-01), pages 631 - 635, XP002927453, DOI: doi:10.1038/39369 *
ZHANG H. ET AL.: "Cellular response to hypoxia involves signaling via Smad proteins", BLOOD, vol. 101, no. 6, March 2003 (2003-03-01), pages 2253 - 2260 *

Also Published As

Publication number Publication date
WO2008046964A2 (fr) 2008-04-24
WO2008046964A8 (fr) 2009-07-30

Similar Documents

Publication Publication Date Title
EP1987141B8 (fr) Compositions de traitement des maladies médiées par le collagène
AP2332A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors.
AP2007003973A0 (en) Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation
EP2214770A4 (fr) Procédés, kits et compositions pour administrer des composés pharmaceutiques
IL182837A0 (en) Methods, assays and compositions for treating retinol-related diseases
WO2007081740A3 (fr) Méthodes et compositions basés sur des micro-arn et s'appliquant au diagnostic et au traitement de cancers solides
WO2008097277A3 (fr) Expression tcl1 dans la leucémie lymphocytaire chronique (llc) régulée par mir-29 et mir-181
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
AU2007288337A8 (en) Compounds for treating proliferative disorders
WO2010104598A3 (fr) Inhibiteurs de la liaison à une protéine kinase
WO2008038127A8 (fr) Composés se liant aux molécules d'adhérence jonctionnelles c (jam-c) et procédés d'utilisation correspondants
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2007059230A3 (fr) 1h-benzimidazole-4-carboxamides substitues efficaces en tant qu’inhibiteurs de parp
WO2008075173A3 (fr) Méthodes de traitement de troubles liés au podocyte
EP2101567A4 (fr) Compositions et procédés pour détecter, traiter ou prévenir le stress réductif
WO2008013660A3 (fr) Inhibiteurs de produits de glycation avancée
WO2008011483A3 (fr) Procédés de traitement de la douleur chronique à l'aide de 1-aryl-1-hydroxy 2,3-diamino-propyl amines, de 1-hétéroaryl-1-hydroxy-2,3-diamino-propyl amines et de composés apparentés
IL183931A0 (en) Method for detecting mental disorders and pharmaceutical compositions for treating them
WO2007101063A3 (fr) Traitement de troubles liés au développement
WO2006053315A3 (fr) Methodes et compositions de traitement de maladies proliferatives cellulaires
WO2007056625A3 (fr) Inhibiteurs de thienopyridine b-raf kinase
WO2008046964A3 (fr) Nouveaux inhibiteurs utiles
WO2004078180A3 (fr) Inhibiteurs de naaladase pour le traitement de la tolerance aux opiaces
WO2009060451A3 (fr) Dérivés de s-alkylisothiouronium utilisés dans le traitement des troubles liés à l'hypercontractilité utérine
WO2007116029A3 (fr) Association comprenant un composé pyrimidylaminobenzamide et un inhibiteur de kinase thr315lle

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823194

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07823194

Country of ref document: EP

Kind code of ref document: A2